Category Archives: Partners PrEP

  1. The road to PrEP: trials, regulation and roll-out

    via aidsmap.com, by Gus Cairns Within the next three years, up to 33,000 people may take part in 22 different studies worldwide to demonstrate the feasibility, or otherwise, of pre-exposure prophylaxis (PrEP) to prevent HIV, the IAPAC evidence summit, Controlling the HIV epidemic with antiretrovirals, was told on 12 June.Some of these studies are underway but others Read More >>

    ARVs, hiv prevention, MSM, Partners PrEP, PrEP, Tenofovir, Truvada
  2. Meet Peter – A Friendly Rectal Microbicide Advocate from Kenya

    Check out this interesting mini-bio of Peter Michira, the latest IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Peter is one of six new bios just posted yesterday, including individuals from Thailand, India, the UK, the US and Argentina. Each will be featured on the blog, and you can read all of Read More >>

    hiv prevention, IRMA, Kenya, Meet a Friendly Rectal Microbicide Advocate, Partners PrEP, Project ARM
  3. An Analysis of PrEP Data and Decisions Taken in 2011

    via Treatment Issues, by Deirdre Grant More than a decade ago, “AIDS Drugs for Africa” was one of the rallying cries for a global activist movement.The meaning was simple: treat HIV-positive people with potent, life-saving medications regardless of where they live, how much money they have or who they love. These days, the phrase has more meanings Read More >>

    ARV, clinical trials, Microbicides, Partners PrEP, pre-exposure prophylaxis, PrEP, testing
  4. Two Studies Show the Importance of Adherence in PrEP at CROI 2012

    via AidsMap.com, by Gus Cairnes Adherence makes all the difference to the efficacy of pre-exposure prophylaxis (PrEP), the 19th Conference on Retroviruses and Opportunistic Infections (CROI) heard today. Further data were presented from two trials of PrEP (giving anti-HIV drugs to HIV-negative people to prevent infection), which announced dramatically different results last year. In April 2011, the Read More >>

    CROI, FEM-PrEP, HIV/AIDS. pre-exposure prophylaxis, Partners PrEP, pre-exposure prophylaxis, PrEP, Tenofovir, Truvada
  5. CROI 2012: Recent Results Presented by Partners PrEP Study

    via MedPage Today, by Michael Smith Giving anti-retroviral drugs to HIV-negative people can reduce their risk of acquiring the virus from an HIV-positive partner, a researcher said here. In a large randomized controlled trial in Africa, this type of pre-exposure prophylaxis, or PrEP, cut the risk of infection by up to 75% compared with placebo, according to Read More >>

    ARV, ARVs, CROI, HPTN052, Partners PrEP, PrEP
  6. Differing Truvada Drug Levels in Vaginal and Rectal Tissue Offer Clues to HIV PrEP Puzzle

    via HIVandHepatitis.com, by Liz Highleyman The 2 drugs in the Truvada pill — tenofovir and emtricitabine — reach different concentrations in human cervical, vaginal, and rectal mucosa tissues and fluids, according to new research published in the December 7, 2011, issue of Science Translational Medicine. Lower drug levels in the female genital tract suggest that women may Read More >>

    Africa, FEM-PrEP, iPrEx, Partners PrEP, PrEP, rectal transmission, TDF2, Truvada
  7. Washington D.C.: Public Meeting on Safety Issues in PrEP

    An invitation from the Forum for Collaborative HIV Research: Safety Issues in Pre-exposure Prophylaxis for HIV negative individuals, proposals for management of safety concerns, and pending plans for scale-up Forum for Collaborative HIV Research 1608 Rhode Island Avenue, NW Washington, DC 20036 August 19, 2011 8:30am – 4:00pm The Forum for Collaborative HIV Research has been tasked Read More >>

    Forum for Collaborative HIV Research, HIV/AIDS, iPrEx, new prevention technologies, Partners PrEP, pre-exposure prophylaxis, PrEP, prevention, safety, study, TDF2
  8. Open-Label Extension of iPrEX HIV PrEP Study Begins at 11 Sites in 6 Countries

    Via iPrEX News. The iPrEx Open-Label Extension Study (iPrEx OLE), the next phase of the first human study to report efficacy results on pre-exposure prophylaxis (PrEP) to prevent HIV infection, has begun at clinical trial sites around the world. Approximately 2,000 men and transgender women who have sex with men are expected to participate in the 72-week Read More >>

    Africa, FEM-PrEP, HIV, iPrEx, iPrEx OLE, new prevention technologies, Partners PrEP, prevention, TDF2, Treatment
  9. PrEP Media Round-Up – It Works for Heterosexuals Too!

    [UPDATED JULY 18] The exciting news was announced last week that pre-exposure prophylaxis has been shown to work for heterosexual men and women as well as MSM. This is HUGE for HIV prevention. Below is a selection of news items and press releases we have collected on the two studies that reported out last week. In the comments feel Read More >>

    Africa, Gilead, heterosexual epidemic, HIV, HIV transmission, HIV/AIDS, HIV/AIDS policy, iPrEx, new prevention technologies, Partners PrEP, PrEP, prevention, Tenofovir, Truvada
  10. Two studies show that drugs used to treat AIDS can be used to prevent HIV infection, too

    [THIS IS HUGE!] via Washington Post, by David Brown Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person’s chance of becoming infected with HIV through heterosexual intercourse. The results, announced early Wednesday, provide more evidence that the drugs responsible Read More >>

    Africa, heterosexual epidemic, HIV/AIDS. pre-exposure prophylaxis, new prevention technologies, partners, Partners PrEP, PrEP